Everence Capital Management Inc. Lowers Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Everence Capital Management Inc. trimmed its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 18.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 5,380 shares of the company’s stock after selling 1,250 shares during the period. Everence Capital Management Inc.’s holdings in Prestige Consumer Healthcare were worth $420,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in PBH. Geode Capital Management LLC lifted its stake in Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after purchasing an additional 50,961 shares in the last quarter. Lombard Odier Asset Management USA Corp acquired a new position in Prestige Consumer Healthcare during the 2nd quarter worth about $550,000. Sequoia Financial Advisors LLC grew its position in Prestige Consumer Healthcare by 12.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock valued at $708,000 after acquiring an additional 1,120 shares in the last quarter. Barclays PLC increased its stake in Prestige Consumer Healthcare by 346.3% during the third quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after purchasing an additional 71,730 shares during the period. Finally, Pinnacle Associates Ltd. lifted its position in shares of Prestige Consumer Healthcare by 60.3% during the third quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company’s stock worth $1,776,000 after purchasing an additional 9,269 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. StockNews.com lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Monday, December 30th. DA Davidson restated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research note on Monday, December 9th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $85.25.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 9,885 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the sale, the senior vice president now directly owns 18,835 shares of the company’s stock, valued at approximately $1,543,904.95. This represents a 34.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now directly owns 18,365 shares in the company, valued at $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock worth $3,187,300 over the last 90 days. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $76.88 on Monday. The business has a 50 day moving average price of $80.50 and a 200 day moving average price of $74.01. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of 18.71, a PEG ratio of 2.32 and a beta of 0.51. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.95 and a fifty-two week high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. The business had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company’s revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.07 EPS. Equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.